Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs. The W4 and D4 splitters each enable multi-site placement of up to four leads, which are designed to deliver electrical pulses to the spinal cord that mask pain signals to the brain. The products will be introduced at the 12th annual meeting of the American Society of Interventional Pain Physicians (ASIPP), June 26 – 30 in Arlington, Virginia.
The new splitters offer a broader range of lead configurations and are designed to provide physicians more treatment options for their chronic pain patients.
"Spinal cord stimulation is an important treatment option for chronic pain," said Giancarlo Barolat, M.D., Medical Director of Barolat Neuroscience in Denver. "Boston Scientific's lead splitters give pain management physicians more choices to help optimize pain relief when using the Precision Plus System."
"Our goal is to design products that provide lasting pain relief for patients," said Michael Onuscheck, Senior Vice President and President of Boston Scientific's Neuromodulation Division. "We are pleased to introduce this expanded line of splitters for multi-site SCS lead placement."
Pain is the most common reason Americans seek medical treatment, and an estimated 26 million Americans experience frequent back pain. Many chronic pain patients have found that SCS helps them manage their pain and live better lives.
Boston Scientific will present its full line of Neuromodulation products at booth #22/43 at the ASIPP annual meeting.
Ultra-processed foods raise chronic kidney disease risk, study shows